Tyra Biosciences, Inc.
TYRA
$25.38
$0.361.42%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.14% | 21.57% | 23.66% | 35.09% | 35.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.90% | 25.66% | 27.41% | 25.87% | 27.45% |
| Operating Income | -31.90% | -25.66% | -27.41% | -25.87% | -27.45% |
| Income Before Tax | -40.38% | -35.95% | -38.70% | -33.37% | -30.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.38% | -35.95% | -38.70% | -33.37% | -30.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.38% | -35.95% | -38.70% | -33.37% | -30.86% |
| EBIT | -31.90% | -25.66% | -27.41% | -25.87% | -27.45% |
| EBITDA | -32.06% | -25.78% | -27.52% | -25.92% | -27.45% |
| EPS Basic | -33.90% | -33.06% | -33.44% | -17.01% | -5.63% |
| Normalized Basic EPS | -33.90% | -33.07% | -33.45% | -17.02% | -5.63% |
| EPS Diluted | -33.90% | -33.06% | -33.44% | -17.01% | -5.63% |
| Normalized Diluted EPS | -33.90% | -33.07% | -33.45% | -17.02% | -5.63% |
| Average Basic Shares Outstanding | 4.40% | 2.06% | 4.18% | 11.70% | 20.38% |
| Average Diluted Shares Outstanding | 4.40% | 2.06% | 4.18% | 11.70% | 20.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |